Protalix Biotherapeutics, Inc. (PLX)
2.475
+0.08
(+3.12%)
USD |
NYAM |
Aug 26, 16:00
2.475
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Debt to Equity Ratio : 0.1289 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1289 |
| March 31, 2026 | 0.1262 |
| December 31, 2025 | 0.1725 |
| September 30, 2025 | 0.1546 |
| June 30, 2025 | 0.1072 |
| March 31, 2025 | 0.1158 |
| December 31, 2024 | 0.1279 |
| September 30, 2024 | 0.1752 |
| June 30, 2024 | 0.915 |
| March 31, 2024 | 0.8854 |
| December 31, 2023 | 0.7829 |
| September 30, 2023 | 0.68 |
| June 30, 2023 | 0.6659 |
| March 31, 2023 | 33.30 |
| December 31, 2022 | -3.146 |
| September 30, 2022 | -2.878 |
| June 30, 2022 | -3.338 |
| March 31, 2022 | -4.461 |
| December 31, 2021 | -5.545 |
| September 30, 2021 | 172.45 |
| June 30, 2021 | 16.17 |
| March 31, 2021 | 4.211 |
| December 31, 2020 | -2.382 |
| September 30, 2020 | -1.907 |
| June 30, 2020 | -1.800 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.998 |
| December 31, 2019 | -0.8664 |
| September 30, 2019 | -0.7892 |
| June 30, 2019 | -0.8179 |
| March 31, 2019 | -0.9093 |
| December 31, 2018 | -0.9071 |
| September 30, 2018 | -0.987 |
| June 30, 2018 | -1.094 |
| March 31, 2018 | -1.320 |
| December 31, 2017 | -1.668 |
| September 30, 2017 | -2.449 |
| June 30, 2017 | -2.800 |
| March 31, 2017 | -1.716 |
| December 31, 2016 | -7.785 |
| September 30, 2016 | -4.796 |
| June 30, 2016 | -9.067 |
| March 31, 2016 | 27.25 |
| September 30, 2015 | -0.9892 |
| June 30, 2015 | -1.039 |
| March 31, 2015 | -1.105 |
| December 31, 2014 | -1.213 |
| September 30, 2014 | -1.412 |
| June 30, 2014 | -1.690 |
| March 31, 2014 | -2.000 |
| December 31, 2013 | -2.488 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Altimmune, Inc. | 0.076 |
| Taysha Gene Therapies, Inc. | 0.1469 |
| Humacyte, Inc. | 2.117 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 110.34M |
| Total Liabilities (Quarterly) | 38.93M |
| Shareholders Equity (Quarterly) | 71.40M |
| Current Ratio | 2.938 |
| Net Debt Paydown Yield | -0.42% |